For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Antibody panels for immune checkpoints

Related

  • Immuno-oncology resources
    • IO ELISA kits and reagents
      • IO antibodies for your pipeline
        • PD-L1 clone comparison
          • PD-L1 protocols for automated IHC
            • PD-L1 primary antibody conjugates
              • Carrier-free formulations for recombinant antibodies
                • Tools for IO research

                  ​Multiple clones. Multiple opportunities. One purchase. ​  

                  ​Immune checkpoints are critical molecules that modulate the T-cell-stimulatory signals of the immune response1. Since many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies, providing a promising approach to activating therapeutic antitumor immunity2.   


                  Increase your chances of success and do more with your screening
                  ​

                  Discover our range of hand-picked antibody panels to key immuno-oncology targets designed to save you time and provide you with easy access to the best selection of clones on the market. Each panel contains a selection of monoclonal antibodies that detect the same protein to increase your chances of finding a compatible clone for your assay with just one purchase. 

                  We eliminate the need for pre-screening by narrowing our catalog to the most suitable, IHC-optimized clones and packaging into an easily accessible kit so you can get on with determining the best antibody for your IHC research assay needs. 
                  ​

                  Find your target



                  ​​280x200-CMS-Image-TIM-3.png​​

                  TIM-3

                  Recent studies have highlighted that TIM-3 has an important role to play in T-cell exhaustion and correlates with the outcome of anti-PD-1 therapy, therefore targeting TIM-3 might be a promising approach for cancer immunotherapy3.

                  Our TIM-3 antibody panel contains three recombinant monoclonal antibodies against human TIM-3. 


                  280x200-CMS-Image-LAG-3.png​​

                  LAG-3

                  LAG-3 ensures immune homeostasis through suppressing T-cell activation and cytokine secretion. Immunotherapies targeting LAG-3 are moving forward into clinical trials, and combination immunotherapy of anti-LAG-3 and anti-PD-1 is showing promising efficacy in overcoming resistance to PD-1 immunotherapy4.

                  Our LAG-3 antibody panel contains six recombinant monoclonal antibodies to human LAG-3. 


                  280x200-CMS-GITR (003).png​

                  GITR

                  GITR is a co-stimulatory cell surface receptor which is expressed by T-cells and natural killer cells. GITR modulation in preclinical models has shown promising antitumor activity by stimulating effector T-cells and suppressing regulatory T-cells5.

                  Our GITR antibody panel contains three recombinant monoclonal antibodies to human GITR. 


                  280x200-CMS-PDL1-4.png​

                  PD-L1

                  The PD-1/PD-L1 pathway plays a key role in physiological immune homeostasis and provide a means through which cancer can evade the immune system. The development and application of immune checkpoint inhibitors that block PD-1/PD-L1 interaction result in very durable responses in a wide range of cancers and prolong survival in a subset of patients6 .

                  Our PD-L1 antibody panel contains four recombinant monoclonal antibodies to human PD-L1 including highly cited and best-in-class clones 28-8, SP142, and 73-10. 


                  280x200-CMS-PDL1-5.png​

                  PD-1

                  PD-1 is the receptor to transmembrane ligand PD-L1 and is expressed on the surface of T-cells. Cancer cells may exploit the PD-1/PD-L1 interaction to evade and suppress the immune response. Inhibition of the PD-1 pathway is increasingly being adopted as a therapeutic approach to treat cancers7.

                  Our PD-1 antibody panel contains five monoclonal antibodies to human PD-1 including the top-cited NAT105 clone. 

                  ​​

                  ​

                  View our full range of antibody panels.

                  Once you have established the best clone for your assay, get in contact to start the conversation on how we can support you through your pipeline with flexible formats, scale-up options, custom conjugations, and support for commercial partnerships.

                  References

                  1. Zhao, X. and Subramanian, S. Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy​. Cancer Research. (2017). 

                  2. Pardoll, D. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12, 252–264 (2012). 

                  3. He, Yayi et al. TIM-3, a promising target for cancer immunotherapy. OncoTargets and therapy vol. 11 7005-7009. (2018). 

                  4. Long L, Zhang X, Chen F, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5-6):176–189.  

                  5. Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.  

                  6. Rizvi, Naiyer A et al. “Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.” The Lancet. Oncology vol. 16,3 (2015): 257-65. 

                  7. Akinleye, A., Rasool, Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12, 92 (2019). 




                  ​​




                  Get resources and offers direct to your inbox Sign up
                  A-Z by research area
                  • Cancer
                  • Cardiovascular
                  • Cell biology
                  • Developmental biology
                  • Epigenetics & Nuclear signaling
                  • Immunology
                  • Metabolism
                  • Microbiology
                  • Neuroscience
                  • Signal transduction
                  • Stem cells
                  A-Z by product type
                  • Primary antibodies
                  • Secondary antibodies
                  • Biochemicals
                  • Isotype controls
                  • Flow cytometry multi-color selector
                  • Kits
                  • Loading controls
                  • Lysates
                  • Peptides
                  • Proteins
                  • Slides
                  • Tags and cell markers
                  • Tools & Reagents
                  Help & support
                  • Support
                  • Make an Inquiry
                  • Protocols & troubleshooting
                  • Placing an order
                  • RabMAb products
                  • Biochemical product FAQs
                  • Training
                  • Browse by Target
                  Company
                  • Corporate site
                  • Investor relations
                  • Company news
                  • Careers
                  • About us
                  • Blog
                  Events
                  • Tradeshows
                  • Conferences
                  International websites
                  • abcam.cn
                  • abcam.co.jp

                  Join with us

                  • LinkedIn
                  • facebook
                  • Twitter
                  • YouTube
                  • Terms of sale
                  • Website terms of use
                  • Cookie policy
                  • Privacy policy
                  • Legal
                  • Modern slavery statement
                  © 1998-2022 Abcam plc. All rights reserved.